Deep TMS News - Get The Latest News On BrainsWay's Deep TMS

News & Events

March 15, 2020

BrainsWay Announces Positive Data from Smoking Cessation Multicenter Study Evaluating Use of Deep TMS at Society for Research on Nicotine & Tobacco 2020

Positive results showed that Deep TMS may help chronic smokers quit – Data collected from first multicenter...

February 10, 2020

BrainsWay Reports Results of Interim Analysis of H7 Deep Transcranial Magnetic Stimulation Study in Post-Traumatic Stress Disorder

Company to discontinue funding of study following insufficient demonstration of efficacy

February 10, 2020

BrainsWay Appoints Avner Lushi to Join Board of Directors

Lushi also to serve on Company’s audit committee

February 10, 2020

BrainsWay Announces Data from Feasibility Study of Deep Transcranial Magnetic Stimulation System in the treatment of Adults with ADHD

Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s...

December 2, 2019

BrainsWay Announces Successful Results in Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as an Aid in Smoking Cessation

Primary and secondary endpoint achieved with statistical significance. Company intends to meet with...

November 25, 2019

BrainsWay Reports Third Quarter 2019 Financial Results and Operational Highlights

Third quarter revenues were $5.9 million, up 38% over the same quarter in the prior year

November 25, 2019

BrainsWay Appoints Medical Technology Industry Leader Christopher R. von Jako, Ph.D., as President and Chief Executive Officer

JERUSALEM and HACKENSACK, N.J., Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its...

November 25, 2019

BrainsWay‘s New Stimulator for Deep Transcranial Magnetic Stimulation Makes German Debut at the 2019 German Association for Psychiatry, Psychotherapy and Psychosomatics Congress

JERUSALEM, Nov. 25, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced...

October 1, 2019

BrainsWay Announces Innovative Deep Transcranial Magnetic Stimulation System Showcase Presentation at this Year’s Psych Congress Meeting

JERUSALEM, Oct. 01, 2019 – BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced...

September 19, 2019

BrainsWay Announces Further Leadership Transition to U.S.

Company Intends to Appoint U.S.-Based CEO

August 26, 2019

BrainsWay Reports Second Quarter 2019 Financial Results and Operational Highlights

Company also announces changes to U.S. Management Team

July 18, 2019

Groundbreaking Study Demonstrates Advantages of BrainsWay Deep TMS in Treating Major Depressive Disorder

First head-to-head, randomized controlled trial of its kind comparing Deep TMS, TMS and medication in...

June 27, 2019

New Data Published in American Journal of Psychiatry Further Substantiates BrainsWay’s Deep TMS System for the Treatment of Patients with Obsessive Compulsive Disorder

First non-invasive device for OCD achieves 45% response rate among patients after one month follow up,...

June 24, 2019

BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder

Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites...

June 13, 2019

BrainsWay To Present At The 2019 Raymond James Life Sciences And MedTech Conference

JERUSALEM and HACKENSACK, N.J., June 13, 2019 – BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay”...

May 22, 2019

BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment

More than 260 participants have been enrolled to the study

March 5, 2019

BrainsWay Announces New Clinical Support Program for Physicians Treating Obsessive-Compulsive Disorder: – “BrainsWay OCD Launchpad to Success”

Program supports physicians in successfully implementing OCD Deep TMS treatment, through in-depth clinical...